Moderna and Merck post first positive Phase 3 for mRNA cancer vaccine in melanoma

Moderna reports first positive Phase 3 for mRNA neoantigen therapy in melanoma

Moderna and Merck announced positive Phase 3 results for intismeran autogene, an individualized mRNA neoantigen therapy, combined with KEYTRUDA, in patients with resected stage IIB-IV melanoma. The trial met its primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival. This marks the first positive Phase 3 for an individualized neoantigen therapy and the first for an mRNA-based cancer therapy. Moderna CEO Noubar Afeyan called it a milestone for the field and for patients.